When it comes to CBN however, the case is a bit different because CBN is yet to be approved as a drug and so it does not fall under the jurisdiction of this law yet. The rule exempts products that are already being marketed as food and dietary supplements which CBN is already been marketed as. This means that since CBN is already been marketed as dietary supplements prior to FDA clinical investigation of CBN as a drug, it won’t be covered under the non-exempt drug rule. This stands sure as long as manufacturers stay clear of unapproved health claims.